Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Graphite Bio, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
08/02/2023 8-K Appointed a new director
07/20/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2023 8-K Quarterly results
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel for Sickle Cell Disease"
12/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
11/09/2022 8-K Quarterly results
Docs: "Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December"
11/03/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/13/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting"
06/23/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/21/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
12/20/2021 8-K Quarterly results
12/08/2021 8-K Quarterly results
11/17/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease GPH101 designed to directly correct the genetic mutation responsible for sickle cell disease"
11/16/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Sublease Agreement between the Registrant and Annexon, Inc."
11/10/2021 8-K Quarterly results
Docs: "Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results Recruitment for Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease underway at multiple sites"
08/12/2021 8-K Quarterly results
06/30/2021 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "Underwriting Agreement",
"Amended and Restated Certificate of Incorporation of Graphite Bio. Inc., effective as of June 29, 2021",
"Amended and Restated Bylaws of Graphite Bio. Inc., effective as of June 24, 2021"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy